Hindering triple negative breast cancer progression by targeting endogenous interleukin‐30 requires IFNγ signaling

• Carlo Sorrentino,
• Stefania Livia Ciummo,
• Luigi D'Antonio,
• Paola Lanuti,
• Scott I. Abrams,
• Zhinan Yin,
• Li‐Fan Lu,
• Emma Di Carlo

Affiliations

Carlo Sorrentino

Department of Medicine and Sciences of Aging “G. d'Annunzio” University Chieti Italy

Stefania Livia Ciummo

Department of Medicine and Sciences of Aging “G. d'Annunzio” University Chieti Italy

Luigi D'Antonio

Department of Medicine and Sciences of Aging “G. d'Annunzio” University Chieti Italy

Paola Lanuti

Department of Medicine and Sciences of Aging “G. d'Annunzio” University Chieti Italy

Scott I. Abrams

Department of Immunology Roswell Park Cancer Institute (RPCI) Buffalo New York USA

Zhinan Yin

The First Affiliated Hospital, Biomedical Translational Research Institute, Guangdong Province Key Laboratory of Molecular Immunology and Antibody Engineering Jinan University Guangzhou China

Li‐Fan Lu

Division of Biological Sciences, Center for Microbiome Innovation and Moores Cancer Center University of California San Diego California USA

Emma Di Carlo

Department of Medicine and Sciences of Aging “G. d'Annunzio” University Chieti Italy